Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers are interested in combining PARP inhibitors with immunotherapies for pancreatic and other cancers with defects in DNA repair.
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.
Lynparza (olaparib) may become standard follow-up therapy for women with newly diagnosed ovarian cancer that has a BRCA mutation.
PARP inhibitor slowed disease progression in clinical study.
The PARP inhibitor Lynparza slows disease progression in women with BRCA-related ovarian cancer.
The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
New treatment options are available for those with breast cancer that has metastasized.
Study shows eight-month survival advantage for those not previously treated with chemotherapy.
Lynparza is now indicated for breast cancer patients with BRCA mutations.
First FDA-approved treatment for patients with BRCA-mutated HER2-negative metastatic breast cancer.
Lynparza (olaparib) was nearly twice as likely as chemotherapy to shrink tumors in women with metastatic breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.